AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 13 592 GBX 0.58% Market Closed
Market Cap: 210.8B GBX

Operating Margin
AstraZeneca PLC

24.3%
Current
21%
Average
6.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
24.3%
=
Operating Profit
14.2B
/
Revenue
58.1B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP
24%
US
Eli Lilly and Co
NYSE:LLY
955.6B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
485.9B USD
27%
CH
Roche Holding AG
SIX:ROG
247.5B CHF
34%
CH
Novartis AG
SIX:NOVN
205.5B CHF
33%
US
Merck & Co Inc
NYSE:MRK
248B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
11%
US
Pfizer Inc
NYSE:PFE
148B USD
29%
FR
Sanofi SA
PAR:SAN
103.5B EUR
24%
No Stocks Found

AstraZeneca PLC
Glance View

AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.

AZN Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
24.3%
=
Operating Profit
14.2B
/
Revenue
58.1B
What is the Operating Margin of AstraZeneca PLC?

Based on AstraZeneca PLC's most recent financial statements, the company has Operating Margin of 24.3%.

Back to Top